Khrystyna Kuzmych

Dr. Khrystyna Kuzmych

General Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DNDania Nachira
Dania Nachira
GPGiovanni Punzo
Giovanni Punzo
GCGiuseppe Calabrese
Giuseppe Calabrese
FSFlaminio Sessa
Flaminio Sessa
MCMaria Teresa Congedo
Maria Teresa Congedo
SMStefano Margaritora
Stefano Margaritora
Background: To evaluate the analgesic efficacy of continuous erector spinae plane block(c-ESPB) and serratus anterior plane block(c-SAPB) versus the intercostal nerve block (ICNB) in Uniportal-VATS in terms of pain control, drug consumption, and complications. Methods: Ninety-three consecutive patients, undergone one of the three peripheral nerve blocks after Uniportal-VATS, were prospectively enrolled. A 1:1 propensity score matching was used to minimize bias. Results: C-ESPB and c-SAPB groups had no difference in morphine request upon awakening compared to ICNB. A higher VAS-score was recorded in c-ESPB compared to ICNB in the first 12 h after surgery. A significantly lower consumption of paracetamol in II postoperative day (p.o.d.) and tramadol in I and II p.o.d. was recorded in the c-ESPB group compared to the ICNB group. A higher dynamic VAS score was recorded at 24 h and 48 h in the ICNB group compared to the c-SAPB. No difference was found in safety, VAS-score and drug consumption between c-ESPB and c-SAPB at any given time, except for a higher tramadol request in c-SAPB in II p.o.d. Conclusions: C-ESPB and c-SAPB appear to have the same safety and analgesic efficacy when compared between them and to ICNB in Uniportal-VATS approach. C-ESPB showed a delayed onset of analgesic effect and a lower postoperative drug consumption compared to ICNB.

12 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DNDania Nachira
Dania Nachira
PBPietro Bertoglio
Pietro Bertoglio
MIMahmoud Ismail
Mahmoud Ismail
ANAntonio Giulio Napolitano
Antonio Giulio Napolitano
GCGiuseppe Calabrese
Giuseppe Calabrese
SMStefano Margaritora
Stefano Margaritora
Objectives: The aim of this study is to evaluate if the efficacy and safety of chest tube placement are influenced by the level of intercostal space insertion (uniportal VATS vs. biportal VATS) or by the type of drain employed (standard vs. smart coaxial drain). Methods: Data on patients who underwent either uniportal or biportal VATS upper lobectomies with lymphadenectomy were prospectively collected in three European centers. The uniportal VATS group with a 28 Fr standard chest tube (U-VATS standard) was compared with the uniportal VATS group with a 28 Fr smart drain (U-VATS smart), and U-VATS smart was also compared with biportal VATS with a 28 Fr smart drain inserted in the VIII intercostal space (Bi-VATS smart). Results: When comparing the U-VATS standard group with the U-VATS smart, a higher fluid output was recorded in the U-VATS smart (p: 0.004) in the III post-operative day (p.o.) and overall (p: 0.027), with a lower 90-day re-admission in the U-VATS smart (p: 0.04). The Bi-VATS smart group compared to U-VATS smart showed a higher fluid output in the I p.o. (p < 0.001), with no difference in total fluid amount or hospitalization. The Bi-VATS smart recorded a lower incidence (p < 0.001) of residual pleural space or effusion (p: 0.004) at chest X-rays prior to drain removal but a higher level of pain and chronic intercostal neuralgia (p: 0.03). Conclusions: Chest tube insertion through the same incision space in uniportal VATS seems to be safe and effective. Smart drains can improve the fluid output in uniportal VATS, as if the drainage were inserted in a lower space (i.e., biportal VATS), but with less discomfort.

10 January 2024 in Life
Verified
Journal Article
Open access
PDF file
DNDania Nachira
Dania Nachira
MCMaria Teresa Congedo
Maria Teresa Congedo
DED’Argento Ettore
D’Argento Ettore
EMElisa Meacci
Elisa Meacci
JEJessica Evangelista
Jessica Evangelista
SMStefano Margaritora
Stefano Margaritora
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Notably, the incidence of lung cancer among never-smokers, predominantly women, has been rising in recent years. Among the various implicated risk factors, human papilloma virus (HPV) may play a role in the development of NSCLC in a certain subset of patients. The prevalence of high-risk HPV-DNA within human neoplastic lung cells varies across the world; however, the carcinogenetic role of HPV in NSCLC has not been completely understood. Bloodstream could be one of the routes of transmission from infected sites to the lungs, along with oral (through unprotected oral sex) and airborne transmission. Previous studies reported an elevated risk of NSCLC in patients with prior HPV-related tumors, such as cervical, laryngeal, or oropharyngeal cancer, with better prognosis for HPV-positive lung cancers compared to negative forms. On the other hand, 16% of NSCLC patients present circulating HPV-DNA in peripheral blood along with miRNAs expression. Typically, these patients have a poorly differentiated NSCLC, often diagnosed at an advanced stage. However, HPV-positive lung cancers seem to have a better response to target therapies (EGFR) and immune checkpoint inhibitors and show an increased sensitivity to platinum-based treatments. This review summarizes the current evidence regarding the role of HPV in NSCLC development, especially among patients with a history of HPV-related cancers. It also examines the diagnostic and prognostic significance of HPV, investigating new future perspectives to enhance cancer screening, diagnostic protocols, and the development of more targeted therapies tailored to specific cohorts of NSCLC patients with confirmed HPV infection.

26 February 2025 in Life
Verified
Journal Article
Open access
PDF file
Khrystyna KuzmychKhrystyna Kuzmych
Khrystyna Kuzmych
DNDania Nachira
Dania Nachira
AEAmelia Evoli
Amelia Evoli
RIRaffaele Iorio
Raffaele Iorio
CSCarolina Sassorossi
Carolina Sassorossi
EMElisa Meacci
Elisa Meacci
Background: While the safety and feasibility of robotic thymectomy have been well documented through several studies, the surgical and long-term neurological outcomes in patients with thymomatous myasthenia gravis (MG), particularly in advanced stages, remain scarce. This study aims to evaluate the surgical outcomes in patients undergoing robotic-assisted thymectomy (RATS) for thymoma and to analyze neurological outcomes in patients with myasthenia. Material and Methods: Out of 128 robotic thymectomies performed at our institution between October 2013 and January 2022, clinical and pathological data from 55 patients diagnosed with thymoma were reviewed. Of these, thirty (54.5%) patients had concomitant acetylcholine-receptor-antibody-associated MG. Neurological outcomes were assessed using the Myasthenia Gravis Foundation of America post-intervention score (MGFA-PIS). Results: Thirty-nine (70.9%) procedures were performed using the left-sided approach. The mean operative time was 196.9 ± 79.9 min in patients with MG compared to 175.8 ± 61.6 min in non-MG patients (p = 0.285). Additionally, patients with MG had a longer in-hospital stay (4.8 ± 2.6 vs. 3.3 ± 2.2 days, p = 0.01) and a significantly higher need for intensive care unit admission (p < 0.01). No deaths were reported. The rates of conversions (3.3% vs. 4.0%, p = 0.895) and complications (p = 0.813) were comparable between the myasthenic and non-myasthenic thymomas. A multivariable analysis identified lung involvement (p = 0.023), vascular involvement (p = 0.04), and extended resection (p = 0.019) as significant risk factors for conversion and complications. The mean age of surgery for patients with MG was 54.5 ± 15.9 years. After a mean follow-up period of 35.6 ± 25.7 months, 18 (60%) patients with myasthenia showed clinical improvement of their condition. Specifically, 2 patients (6.6%) achieved complete stable remission (CSR), 2 (6.6%) experienced pharmacological remission (PR), 12 (40.0%) demonstrated minimal manifestation (MM), and 4 (13.3%) exhibited a combination of PR and MM. Twelve patients (40%) exhibited no changes, maintaining a stable clinical condition. No clinical worsening was observed. The overall improvement rates at 2 years and 5 years were 38% and 83%, respectively. Conclusions: RATS thymectomy is a safe and feasible approach for patients with thymoma. Patients with coexisting MG may benefit through a good rate of neurological improvement.

26 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EMElisa Meacci
Elisa Meacci
MRMajed Refai
Majed Refai
DNDania Nachira
Dania Nachira
MSMichele Salati
Michele Salati
Khrystyna KuzmychKhrystyna Kuzmych
Khrystyna Kuzmych
SMStefano Margaritora
Stefano Margaritora
Background: Completion lobectomy (CL) following a prior resection in the same lobe may be complicated by severe pleural or hilar adhesions. The role of uniportal video-assisted thoracoscopic surgery (U-VATS) has never been evaluated in this setting. Methods: Data were collected from two Italian centers. Between 2015 and 2022, 122 patients (60 men and 62 women, median age 67.7 ± 8.913) underwent U-VATS CL at least 4 weeks after previous lung surgery. Results: Twenty-eight (22.9%) patients were affected by chronic obstructive pulmonary disease (COPD) and twenty-five (20.4%) were active smokers. Among the cohort, the initial surgery was performed using U-VATS in 103 (84.4%) patients, triportal-VATS in 8 (6.6%), and thoracotomy in 11 (9.0%). Anatomical segmentectomy was the initial surgery in 46 (37.7%) patients, while hilar lymphadenectomy was performed in 16 (13.1%) cases. CL was performed on 110 (90.2%) patients, segmentectomy on 10 (8.2%), and completion pneumonectomy on 2 (1.6%). Upon reoperation, moderate pleural adhesions were observed in 38 (31.1%) patients, with 2 (1.6%) exhibiting strong adhesions. Moderate hilar adhesions were found in 18 (14.8%) patients and strong adhesions in 11 (9.0%). The median operative time was 203.93 ± 74.4 min. In four (3.3%) patients, PA taping was performed. One patient experienced intraoperative bleeding that did not require conversion to thoracotomy. Conversion to thoracotomy was necessary in three (2.5%) patients. The median postoperative drainage stay and postoperative hospital stay were 5.67 ± 4.44 and 5.52 ± 2.66 days, respectively. Postoperative complications occurred in 34 (27.9%) patients. Thirty-day mortality was null. Histology was the only factor found to negatively influence intraoperative outcomes (p = 0.000). Factors identified as negatively impacting postoperative outcomes at univariate analyses were male sex (p = 0.003), age > 60 years (p = 0.003), COPD (p = 0.014), previous thoracotomy (p = 0.000), previous S2 segmentectomy (p = 0.001), previous S8 segmentectomy (p = 0.008), and interval between operations > 5 weeks (p= 0.005). In multivariate analysis, only COPD confirmed its role as an independent risk factor for postoperative complications (HR: 5.12, 95% CI (1.07–24.50), p = 0.04). Conclusions: U-VATS CL seems feasible and safe after wedge resection and anatomical segmentectomy.

1 May 2025 in Journal of Visualized Surgery
Verified
Journal Article
Open access
PDF file
Khrystyna KuzmychKhrystyna Kuzmych
Khrystyna Kuzmych
DNDania Nachira
Dania Nachira
MCMaria Teresa Congedo
Maria Teresa Congedo
GCGiuseppe Calabrese
Giuseppe Calabrese
ASAlessia Senatore
Alessia Senatore
EMElisa Meacci
Elisa Meacci
Minimally invasive thoracic surgery has evolved significantly over the past two decades, with robotic-assisted thoracic surgery (RATS) emerging as a leading approach due to its enhanced visualization, wristed instrumentation, and improved ergonomics. Traditional multiport RATS relies on three or four incisions, while uniportal RATS (U-RATS) offers a less invasive approach but presents technical challenges, including instrument crowding and limited stapler manoeuvrability. The development of biportal RATS (Bi-RATS) represents a balance between these techniques, offering improved ergonomics while reducing access-related trauma. This approach has been employed for diverse pulmonary resections—ranging from wedge resections in peripheral nodules to complex anatomic segmentectomies and lobectomies. This manuscript provides a comprehensive overview of Bi-RATS for lung segmentectomies, detailing patient positioning, port placement, intraoperative technique, and the role of advanced imaging adjuncts such as near-infrared fluorescence [indocyanine green (ICG)] and three-dimensional computed tomography (3D CT) reconstruction. By leveraging these advancements, thoracic surgeons can achieve improved outcomes and enhanced decision-making during complex resections. Compared to multiport RATS, U-RATS, and video-assisted thoracoscopic surgery (VATS), Bi-RATS offers improved instrument manoeuvrability, a more ergonomic stapler trajectory, and utilizes anterior port placement in such a way as to reducing intercostal nerve compression, which may lead to lower postoperative pain. It allows for a fully robotic stapling process, minimizing the need for manual staplers and excessive lung manipulation. The integration of ICG fluorescence further refines segmental plane identification, ensuring precise and safe parenchymal division. Postoperative management includes adherence to enhanced recovery after surgery (ERAS) protocols, early chest tube removal, and effective pain control, which contribute to shorter hospital stays and faster patient recovery. Despite a steep learning curve, Bi-RATS optimizes robotic thoracic surgery by enhancing surgical efficiency while minimizing access trauma. Future research should focus on long-term oncological outcomes, cost-effectiveness, and training standardization to establish Bi-RATS as a widely adopted technique in modern thoracic surgery.